to-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases

Dutch brain drug delivery company to-BBB has signed an agreement for a research collaboration with Genzyme Corporation. The project will evaluate to-BBB’s proprietary G-Technology™, which is intended to improve delivery of biologics for neurodegenerative diseases. Biological drugs are important medicines in the treatment of brain diseases, but their effectiveness has been impeded by the inability of these drugs to pass the blood-brain barrier (BBB). to-BBB’s technology is designed to transport different classes of drugs across the BBB by formulating them into proprietary glutathione-coated liposomes. “We look forward to collaborating with Genzyme” says Willem van Weperen, CEO of to-BBB. “Combining the expertise of Genzyme in neurodegenerative diseases with to-BBB’s brain delivery knowledge, should lead to further progress in treating patients with brain diseases with biological drugs.”

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail